Déterminants sociaux de la santé : Questions médicales fréquentes
Nom anglais: Social Determinants of Health
Descriptor UI:D064890
Tree Number:N01.400.675
Termes MeSH sélectionnés :
Complement C5
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Déterminants sociaux de la santé : Questions médicales les plus fréquentes",
"headline": "Déterminants sociaux de la santé : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Déterminants sociaux de la santé : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-20",
"dateModified": "2025-04-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Déterminants sociaux de la santé"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Santé",
"url": "https://questionsmedicales.fr/mesh/D006262",
"about": {
"@type": "MedicalCondition",
"name": "Santé",
"code": {
"@type": "MedicalCode",
"code": "D006262",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N01.400"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Déterminants sociaux de la santé",
"alternateName": "Social Determinants of Health",
"code": {
"@type": "MedicalCode",
"code": "D064890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mofya S Diallo",
"url": "https://questionsmedicales.fr/author/Mofya%20S%20Diallo",
"affiliation": {
"@type": "Organization",
"name": "Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles, Keck School of Medicine at the University of Southern California, 4650 Sunset Boulevard, MS#3, Los Angeles, CA 90027, USA. Electronic address: modiallo@chla.usc.edu."
}
},
{
"@type": "Person",
"name": "Sacharitha Bowers",
"url": "https://questionsmedicales.fr/author/Sacharitha%20Bowers",
"affiliation": {
"@type": "Organization",
"name": "Division of Dermatology, Department of Internal Medicine, Loyola University Medical Center, Stritch School of Medicine, 1S260 Summit Ave, Oakbrook Terrace, IL 60181, USA. Electronic address: sachbow@gmail.com."
}
},
{
"@type": "Person",
"name": "Aileen Y Chang",
"url": "https://questionsmedicales.fr/author/Aileen%20Y%20Chang",
"affiliation": {
"@type": "Organization",
"name": "Department of Dermatology, University of California San Francisco, Zuckerberg San Francisco General Hospital, 995 Potrero Avenue, Building 90, Ward 92, San Francisco, CA 94110, USA."
}
},
{
"@type": "Person",
"name": "Christina Pardo",
"url": "https://questionsmedicales.fr/author/Christina%20Pardo",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA. Electronic address: chp4022@med.cornell.edu."
}
},
{
"@type": "Person",
"name": "Julianne Holt-Lunstad",
"url": "https://questionsmedicales.fr/author/Julianne%20Holt-Lunstad",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, Brigham Young University, Provo, Utah, USA; email: julianne_holt-lunstad@byu.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.",
"datePublished": "2023-04-18",
"url": "https://questionsmedicales.fr/article/37072660",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12325-023-02510-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.",
"datePublished": "2023-02-07",
"url": "https://questionsmedicales.fr/article/36750531",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12325-023-02438-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.",
"datePublished": "2024-08-12",
"url": "https://questionsmedicales.fr/article/39133885",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1212/NXI.0000000000200293"
}
},
{
"@type": "ScholarlyArticle",
"name": "COMPLEMENT-MEDIATED THROMBOTIC MICROANGIOPATHY AFTER KIDNEY TRANSPLANT: SHOULD TREATMENT WITH C5 INHIBITOR BE LIFELONG?",
"datePublished": "2024-04-14",
"url": "https://questionsmedicales.fr/article/38615653",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000538826"
}
},
{
"@type": "ScholarlyArticle",
"name": "Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition.",
"datePublished": "2024-01-27",
"url": "https://questionsmedicales.fr/article/38280096",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40620-023-01873-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Caractéristiques de la population",
"item": "https://questionsmedicales.fr/mesh/D011154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Santé",
"item": "https://questionsmedicales.fr/mesh/D006262"
},
{
"@type": "ListItem",
"position": 4,
"name": "Déterminants sociaux de la santé",
"item": "https://questionsmedicales.fr/mesh/D064890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Déterminants sociaux de la santé - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Déterminants sociaux de la santé",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Déterminants sociaux de la santé",
"description": "Comment évaluer l'impact des déterminants sociaux sur la santé ?\nQuels outils mesurent les déterminants sociaux de la santé ?\nQuels indicateurs sont utilisés pour le diagnostic social ?\nComment les inégalités sociales affectent-elles la santé ?\nQuel rôle joue l'environnement dans le diagnostic social ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Déterminants sociaux de la santé",
"description": "Quels symptômes peuvent indiquer des déterminants sociaux défavorables ?\nComment la pauvreté affecte-t-elle la santé mentale ?\nQuels symptômes physiques sont liés à des conditions sociales ?\nLes inégalités sociales provoquent-elles des symptômes spécifiques ?\nComment l'accès limité aux soins se manifeste-t-il ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Déterminants sociaux de la santé",
"description": "Quelles stratégies de prévention ciblent les déterminants sociaux ?\nComment sensibiliser aux déterminants sociaux de la santé ?\nQuel rôle des communautés dans la prévention ?\nComment les politiques publiques influencent-elles la prévention ?\nQuels programmes de prévention sont efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Déterminants sociaux de la santé",
"description": "Comment adapter les traitements aux déterminants sociaux ?\nQuels traitements sont efficaces pour les populations défavorisées ?\nComment les services de santé peuvent-ils réduire les inégalités ?\nQuel rôle joue l'éducation dans le traitement des maladies ?\nComment les politiques de santé influencent-elles les traitements ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Déterminants sociaux de la santé",
"description": "Quelles complications sont liées aux inégalités sociales ?\nComment les déterminants sociaux aggravent-ils les maladies ?\nQuels sont les effets à long terme des déterminants sociaux ?\nComment prévenir les complications liées aux déterminants sociaux ?\nLes complications de santé sont-elles évitables ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Déterminants sociaux de la santé",
"description": "Quels sont les principaux facteurs de risque sociaux ?\nComment l'éducation influence-t-elle les facteurs de risque ?\nQuel impact a l'emploi sur la santé ?\nComment l'environnement social affecte-t-il la santé ?\nQuels facteurs de risque sont liés à l'accès aux soins ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Complement+C5&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'impact des déterminants sociaux sur la santé ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact peut être évalué par des études épidémiologiques et des enquêtes sociales."
}
},
{
"@type": "Question",
"name": "Quels outils mesurent les déterminants sociaux de la santé ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des questionnaires standardisés et des indices de conditions de vie sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels indicateurs sont utilisés pour le diagnostic social ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les indicateurs incluent le revenu, l'éducation, et l'accès aux soins de santé."
}
},
{
"@type": "Question",
"name": "Comment les inégalités sociales affectent-elles la santé ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inégalités sociales peuvent entraîner des disparités dans l'accès aux soins et la santé."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'environnement dans le diagnostic social ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'environnement physique et social influence la santé par l'accès aux ressources."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer des déterminants sociaux défavorables ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de stress, dépression ou maladies chroniques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment la pauvreté affecte-t-elle la santé mentale ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "La pauvreté peut entraîner une augmentation de l'anxiété et de la dépression."
}
},
{
"@type": "Question",
"name": "Quels symptômes physiques sont liés à des conditions sociales ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies comme l'hypertension et le diabète peuvent être exacerbées par des conditions sociales."
}
},
{
"@type": "Question",
"name": "Les inégalités sociales provoquent-elles des symptômes spécifiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des symptômes de maladies évitables et chroniques."
}
},
{
"@type": "Question",
"name": "Comment l'accès limité aux soins se manifeste-t-il ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il se manifeste par des symptômes non traités et des complications de santé."
}
},
{
"@type": "Question",
"name": "Quelles stratégies de prévention ciblent les déterminants sociaux ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes d'éducation, d'accès aux soins et de soutien communautaire sont essentiels."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser aux déterminants sociaux de la santé ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des campagnes d'information et des formations pour les professionnels de santé."
}
},
{
"@type": "Question",
"name": "Quel rôle des communautés dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les communautés peuvent mobiliser des ressources et créer des réseaux de soutien."
}
},
{
"@type": "Question",
"name": "Comment les politiques publiques influencent-elles la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent promouvoir l'équité en santé et améliorer l'accès aux services."
}
},
{
"@type": "Question",
"name": "Quels programmes de prévention sont efficaces ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les programmes intégrés qui abordent plusieurs déterminants sociaux sont les plus efficaces."
}
},
{
"@type": "Question",
"name": "Comment adapter les traitements aux déterminants sociaux ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements doivent tenir compte des ressources et des conditions de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces pour les populations défavorisées ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les programmes de santé communautaire et les interventions ciblées sont efficaces."
}
},
{
"@type": "Question",
"name": "Comment les services de santé peuvent-ils réduire les inégalités ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "En offrant des soins accessibles et adaptés aux besoins des populations vulnérables."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'éducation dans le traitement des maladies ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation améliore l'adhésion aux traitements et la gestion des maladies."
}
},
{
"@type": "Question",
"name": "Comment les politiques de santé influencent-elles les traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles déterminent l'accès aux soins et les ressources disponibles pour les traitements."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées aux inégalités sociales ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des maladies chroniques non traitées et des décès prématurés."
}
},
{
"@type": "Question",
"name": "Comment les déterminants sociaux aggravent-ils les maladies ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent entraîner un accès limité aux soins et une mauvaise gestion des maladies."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme des déterminants sociaux ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent mener à des problèmes de santé persistants et à une qualité de vie réduite."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux déterminants sociaux ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "En améliorant l'accès aux soins et en renforçant les réseaux de soutien communautaire."
}
},
{
"@type": "Question",
"name": "Les complications de santé sont-elles évitables ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreuses complications peuvent être évitées par des interventions précoces."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque sociaux ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la pauvreté, le manque d'éducation et l'isolement social."
}
},
{
"@type": "Question",
"name": "Comment l'éducation influence-t-elle les facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une éducation supérieure est associée à une meilleure santé et à des comportements préventifs."
}
},
{
"@type": "Question",
"name": "Quel impact a l'emploi sur la santé ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un emploi stable améliore la santé mentale et physique, réduisant les risques."
}
},
{
"@type": "Question",
"name": "Comment l'environnement social affecte-t-il la santé ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un environnement social positif favorise le bien-être et réduit les risques de maladies."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont liés à l'accès aux soins ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le manque d'accès aux soins médicaux et préventifs augmente les risques de maladies."
}
}
]
}
]
}
Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach...
The expert recommendations presented here were created using a Delphi-like process by a group of expert PNH specialists across Central Europe. Based on an initial advisory board meeting discussion, re...
Using a systematic approach, literature databases were searched for relevant studies, and 50 articles were reviewed by the experts and included as supporting evidence....
Implementation of these recommendations uniformly across healthcare institutions will promote the best use of complement inhibition in managing PNH, and has the potential to positively impact patient ...
In the absence of head-to-head trials, this study compared treatment outcomes with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor eculizumab or ravulizumab in complement ...
A matching-adjusted indirect comparison was conducted using individual patient data from the pegcetacoplan arm of the PRINCE trial (NCT04085601; n = 34) and aggregate data from the ravulizumab (n = 12...
After weighting, treatment with pegcetacoplan was associated with statistically significant improvements in most clinical endpoints compared with ravulizumab or eculizumab treatment. These included: g...
Pegcetacoplan provides clinical benefits as first-line treatment for complement inhibitor-naïve patients with PNH....
ClinicalTrials.gov identifier, NCT04085601....
In myelin oligodendrocyte glycoprotein IgG-associated disease (MOGAD) and aquaporin-4 IgG+ neuromyelitis optica spectrum disorder (AQP4+NMOSD), the autoantibodies are mainly composed of IgG1, and comp...
CSF-C3a, CSF-C4a, CSF-C5a, and CSF-C5b-9 levels during the acute phase before treatment in patients with MOGAD (n = 12), AQP4+NMOSD (n = 11), multiple sclerosis (MS) (n = 5), and noninflammatory neuro...
CSF-C3a and CSF-C5a levels were significantly higher in MOGAD (mean ± SD, 5,629 ± 1,079 pg/mL and 2,930 ± 435.8 pg/mL) and AQP4+NMOSD (6,017 ± 3,937 pg/mL and 2,544 ± 1,231 pg/mL) than in MS (1,507 ± ...
The complement pathway is activated in both MOGAD and AQP4+NMOSD, but MAC formation is lower in MOGAD, particularly in those with mild attacks, than in AQP4+NMOSD. These findings may have pathogenetic...
Complement-mediated thrombotic microangiopathy (CM-TMA) is a rare and life-threatening complication that can occur in kidney transplant recipients, with various potential triggers including immunosupp...
Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD). Eculizuma...
To identify characteristics associated with treatment response, we analyzed 244 aHUS patients referred to our center. Patients were classified according to the presence/absence of complement abnormali...
Patients had a better outcome with eculizumab compared to conventional treatment, with a response rate of 81.9% vs 56.9%, p < 0.001 and a long-term cumulative incidence of ESKD of 5.8% vs 22.5% (hazar...
Our data show a better outcome in aHUS patients treated with C5-inhibition, particularly in the primary and combined forms, which have a high risk of relapse after discontinuation that is not observed...
Diabetic nephropathy is a common microvascular complication of diabetes mellitus. It is characterized by progressive chronic kidney disease (CKD) with decline of kidney function by hyperfiltration. On...
Complement C5 (C5) is the key component for the complement activation pathway, which is important for innate immunity, and inhibition of C5 is considered to be effective in antibody-mediated rejection...
Like rheumatoid arthritis (RA) in humans, collagen-induced arthritis (CIA) in mice is associated with not only MHC class II genetic polymorphism but also, to some extent, with other loci including gen...
Several diseases caused by the dysregulation of complement activation can be treated with inhibitors of the complement components C5 and/or C3. However, complement is required for serum bactericidal a...
Serum from adults was collected before and after vaccination with the meningococcal serogroup B vaccine 4CMenB and tested for meningococcal killing. Since the B capsular polysaccharide is structurally...
While only a few pre-vaccination sera showed SBA against the tested B meningococcal isolates, 4CMenB vaccination induced potent complement-activating IgG titers against isolates expressing a matching ...
Compared to the SBA triggered by A,C,W,Y capsule polysaccharide conjugate vaccination, SBA against B meningococci expressing a matching fHbp allele was remarkably resilient against the alternative pat...
A potent effector of innate immunity, the complement system contributes significantly to the pathophysiology of traumatic brain injury (TBI). This study investigated the role of the complement cascade...